Alessia Preziosi

Mrs. Alessia Preziosi

Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
SDSerena Dotolo
Serena Dotolo
RARiziero Esposito Abate
Riziero Esposito Abate
CRCristin Roma
Cristin Roma
DGDavide Guido
Davide Guido
APAlessia Preziosi
Alessia Preziosi
NNNicola Normanno
Nicola Normanno
The use of next-generation sequencing (NGS) techniques for variant detection has become increasingly important in clinical research and in clinical practice in oncology. Many cancer patients are currently being treated in clinical practice or in clinical trials with drugs directed against specific genomic alterations. In this scenario, the development of reliable and reproducible bioinformatics tools is essential to derive information on the molecular characteristics of each patient’s tumor from the NGS data. The development of bioinformatics pipelines based on the use of machine learning and statistical methods is even more relevant for the determination of complex biomarkers. In this review, we describe some important technologies, computational algorithms and models that can be applied to NGS data from Whole Genome to Targeted Sequencing, to address the problem of finding complex cancer-associated biomarkers. In addition, we explore the future perspectives and challenges faced by bioinformatics for precision medicine both at a molecular and clinical level, with a focus on an emerging complex biomarker such as homologous recombination deficiency (HRD).

31 May 2024 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
PCPaola Concolino
Paola Concolino
EPElisa De Paolis
Elisa De Paolis
MRMartina Rinelli
Martina Rinelli
GMGiulia Maneri
Giulia Maneri
FBFrancesca Brisighelli
Francesca Brisighelli
AMAngelo Minucci
Angelo Minucci
Paola Concolino, M.Sc., Elisa De Paolis, M.Sc., Martina Rinelli, M.Sc., Giulia Maneri, M.Sc., Francesca Brisighelli, Ph.D., Rita Trozzi, M.D., Simona Duranti, M.D., Luciano Giacò, M.Sc., Maria Piane, M.D., Alessia Preziosi, M.Sc., Arianna Panfili, M.D., Giovanni Scambia, M.D., Camilla Nero, M.D., Maria De Bonis, M.Sc., and Angelo Minucci M.Sc., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0051

Verified
Journal Article
Open access
PDF file
MBMaria De Bonis
Maria De Bonis
PIpierluigi iapicca
pierluigi iapicca
EPElisa De Paolis
Elisa De Paolis
FBFrancesca Brisighelli
Francesca Brisighelli
JEJessica Evangelista
Jessica Evangelista
AMAngelo Minucci
Angelo Minucci
Large genomic rearrangements (LGRs), occurring as copy number alterations (CNAs), represent a clinically relevant class of pathogenic or likely pathogenic variants (P LPVs) in BRCA1/2 (BRCA) genes in ovarian cancer (OC). We evaluated the performance of a high-resolution algorithm integrated into a commercial homologous recombination deficiency (HRD) assay to improve the identification of clinically actionable CNAs in BRCA genes by formalin-fixed paraffin-embedded (FFPE) samples. A total of 760 OC samples were analyzed using a commercial HRD assay incorporating a bioinformatics algorithm for CNA detection. The algorithm was additionally applied to additional homologous recombination repair (HRR) genes, and associations between CNA events and genomic instability (GI) were evaluated. The algorithm demonstrated high sensitivity for both gene and exon-level CNA. The high correlation between CNA positivity cases and GI, in the absence of P/LPVs BRCA single-nucleotide or indels variants, emphasizes the value of integrating CNA detection into routine HRD testing workflows. The extended analysis of additional HRR genes enabled broader characterization of clinically relevant CNAs. This study enables reliable identification of clinically relevant BRCA LGRs from FFPE within HRD testing, supporting a tumor-first diagnostic strategy. This approach may expand the identification of OC patients potentially eligible for PARP inhibitor therapy.